Vision

A more reliable diagnosis of preterm birth risk is one of the biggest unsolved problems in modern obstetrics. Pregnolia's approach is unique and ground-breaking: We work for a simple, reliable and easy to use diagnostic device to fight the burden of preterm birth.

 


Thanks to co-funding from the European Union we can further develop a cost-effective, globally scalable solution.
Our vision is a new preterm birth screening test which will bring relief to doctors and mothers and a better chance to new borns worldwide.

References

Feedback from one of the first established doctor using the Pregnolia measurement device:


«The diagnosis of preterm birth in the low risk population, allowing timely initiation of therapy, is THE unsolved problem in modern obstetrics. We want to offer the Pregnolia System to our patients in order to know who is at risk, and for the best care possible.»


Dr. Bettina von Seefried, Owner of gynhealth GmbH Zürich

Watch the video presentation of Dr. von Seefried.

EU Horizon information

Pregnolia has been awarded a SME Instrument Phase 2 Grant of € 1.28 million. The grant is used to improve the manufacturability of the diagnostic device for the preterm birth risk assessment and to perform activities towards commercial readiness.

Read the interview of Sabrina Badir.

The project runs from September 2019 to June 2022.

Project details can be found here.

EU flag.png

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 873553.

«A diagnostic medical device determining the risk of premature birth - Pregnolia»

EU Horizon information

Pregnolia has been awarded the SME Innovation Associate grant of € 160'000. The grant is used to fund a post-doctoral research associate contributing to the technical and scientific characterization of the Pregnolia System.

The project runs from November 2020 to February 2022.

Project details can be found here.

EU flag.png

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 955931.